Assertio Therapeutics, Inc. (“Assertio” or “the Company”)
(NASDAQ: ASRT) today announced the date of its 2020 Annual Meeting,
which will be held as a virtual meeting on May 19, 2020. The
Company also announced the mailing of a joint proxy
statement/prospectus (the “Joint Proxy Statement/Prospectus”) to
stockholders. At the 2020 Annual Meeting, the Company will ask its
stockholders, among other things, to approve the issuance of shares
to stockholders of Zyla Life Sciences (“Zyla”) in connection with
the Company’s previously announced merger with Zyla (the
“Merger”). Zyla (OTCQX: ZCOR) is planning to hold a Special Meeting
of its stockholders on May 19, 2020 (the “Zyla Special Meeting”),
to approve the Merger. Assertio expects the Merger to close shortly
after the adjournment of the 2020 Annual Meeting and the Zyla
Special Meeting.
The Company reaffirms its ability to achieve the stated target
of upwards of $40 million in cost synergies upon close of the
merger.
The Company also announced that it will release first quarter
2020 financial results on Monday, May 11, 2020, prior to the open
of markets. Following the announcement, the Company will host a
conference call and webcast beginning at 7:30 a.m. central standard
time to discuss its results. Participants can access the live
webcast by visiting http://investor.assertiotx.com.
About the Merger The Merger will create a
leading commercial pharmaceutical company with neurology,
inflammation and pain products. The combined company will have a
leading portfolio of branded non-steroidal anti-inflammatory drugs
(NSAIDs) commonly used by neurologists, orthopedic surgeons,
internists, women’s health providers, podiatrists and pain care
specialists. Together, management intends to build a best-in-class
specialty pharmaceutical company focused on commercial execution.
The combined company will have the platform, profitability and
financial strength to both grow its existing portfolio and acquire
additional complementary assets.
Anticipated Strategic and Financial Benefits of the
Combined Company
- Pro forma 2019 net product sales of approximately $128
million1
- Projected pro forma 2020:
- Non-GAAP adjusted EBITDA margin of greater than 25 percent
- Upwards of $40 million in cost synergies, in addition to
Assertio’s previously announced $15 million in acceleration of cost
savings initiatives
- Expected to result in leading portfolio of NSAIDs given
complementary products
- Positioned to take advantage of trend toward non-opioid pain
products
- Reduced Zyla debt and holding company is expected to have net
debt to EBITDA leverage of two times
- Positioned to add differentiated products through acquisitions
and partnerships
Additional details can be found in Assertio’s and Zyla’s
respective Current Reports of Form 8-K filed with the Securities
and Exchange Commission on March 17, 2020, as well as the Joint
Proxy Statement/Prospectus dated as of April 20, 2020.
First Quarter 2020 Financial Results Audio Conference
Call:Date: May 11, 2020Time: 7:30 a.m. Central TimeU.S.
Dial-in Number: (877) 550-3745International Dial-in Number: (281)
973-6277Conference ID: 4097119
Participants can access the live webcast from the Investor
Relations section of Assertio's website at
http://investor.assertiotx.com. Please access the website 15
minutes prior to the start of the call to download and install any
necessary audio software.
An archived webcast replay will be available on the Company's
website accessed by visiting http://investor.assertiotx.com.
Note Regarding Use of Non-GAAP Financial
MeasuresAssertio and Zyla provide non-GAAP adjusted EBITDA
margin, or earnings before interest, taxes, depreciation and
amortization margin, as a financial measure. Assertio and Zyla
believe that this non-GAAP financial measure, when considered
together with the GAAP figures, can enhance an overall
understanding of Assertio and Zyla's financial performance. The
non-GAAP financial measure is included with the intent of providing
investors with a more complete understanding of operational results
and trends. In addition, this non-GAAP financial measure is among
the indicators each of Assertio’s and Zyla's management uses for
planning and forecasting purposes and measuring their respective
company's performance and which the combined company expects to use
to measure the combined company’s performance. It should be
considered in addition to, and not as a substitute for, or superior
to, financial measures calculated in accordance with GAAP. This
non-GAAP financial measure may be calculated differently from, and
therefore may not be comparable to, non-GAAP financial measures
used by other companies.
About Assertio Therapeutics, Inc.Assertio
Therapeutics is committed to providing responsible solutions to
advance patient care in the Company’s core areas of neurology,
orphan and specialty medicines. Assertio currently markets two
FDA-approved products and continues to identify, license and
develop new products that offer enhanced options for patients that
may be underserved by existing therapies. To learn more about
Assertio, visit www.assertiotx.com.
About Zyla Life SciencesZyla
Life Sciences is a business committed to bringing important
products to patients and healthcare providers. Zyla is focused on
marketing its portfolio of medicines for pain and inflammation. The
company portfolio includes six products: SPRIX® (ketorolac
tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX®
(meloxicam), INDOCIN® (indomethacin) suppositories, INDOCIN® oral
suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use
only - CII. To learn more about Zyla Life Sciences, visit
www.zyla.com.
Forward Looking Statements
Statements in this communication that are not historical facts are
forward-looking statements that reflect Assertio’s and Zyla’s
respective management’s current expectations, assumptions and
estimates of future performance and economic conditions. These
forward-looking statements are made in reliance on the safe harbor
provisions of Section 27A of the Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the Securities Exchange
Act of 1934, as amended. These forward-looking statements relate
to, among other things, future events or the future performance or
operations of Assertio and Zyla, respectively. All statements other
than historical facts may be forward-looking statements; words such
as “anticipate,” “believe,” “could,” “design,” “estimate,”
“expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may”,
“objective,” “opportunity,” “outlook,” “plan,” “position,”
“potential,” “predict,” “project,” “prospective,” “pursue,” “seek,”
“should,” “strategy,” “target,” “would,” “will” or other similar
expressions that convey the uncertainty of future events or
outcomes are used to identify forward-looking statements. Such
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and other factors, some of
which are beyond the control of Assertio or Zyla. Factors that
could cause Assertio’s or Zyla’s actual results (or the actual
results of the new combined company) to differ materially from
those implied in the forward-looking statements include: (1) the
risk that the conditions to the closing of the proposed Merger are
not satisfied, including the risk that required approvals for the
proposed Merger from the stockholders of Assertio or Zyla are not
obtained; (2) the occurrence of any event, change or other
circumstances that either could give rise to the right of one or
both of Assertio or Zyla to terminate the Agreement; (3) the risk
of litigation relating to the proposed Merger; (4) uncertainties as
to the timing of the consummation of the proposed transaction and
the ability of each party to consummate the proposed Merger; (5)
risks related to disruption of management time from ongoing
business operations due to the proposed Merger; (6) unexpected
costs, charges or expenses resulting from the proposed Merger; (7)
the ability of the Assertio and Zyla to retain and hire key
personnel; (8) competitive responses to the proposed Merger and the
impact of competitive services; (9) certain restrictions during the
pendency of the merger that may impact Assertio’s or Zyla’s ability
to pursue certain business opportunities or strategic transaction;
(10) potential adverse changes to business relationships resulting
from the announcement or completion of the proposed transaction;
(11) the combined company’s ability to achieve the growth prospects
and synergies expected from the transaction, as well as delays,
challenges and expenses associated with integrating the combined
company’s existing businesses; (12) negative effects of this
announcement or the consummation of the proposed Merger on the
market price of Assertio’s or Zyla’s common stock, credit ratings
and operating results; (13) legislative, regulatory and
economic developments, including changing business conditions in
the industries in which Assertio and Zyla operate and (14) natural
disasters or calamities, epidemics, pandemics or disease outbreaks
(including COVID-19) or any escalation or worsening of the
foregoing. These risks, as well as other risks associated with the
proposed transaction, will be more fully described in the joint
proxy statement/prospectus that will be filed with the United
States Securities and Exchange Commission (the “SEC”) in connection
with the proposed transaction. Investors and potential investors
are urged not to place undue reliance on forward-looking statements
in this communication, which speak only as of this date. While
Assertio or Zyla may elect to update these forward-looking
statements at some point in the future, each specifically disclaims
any obligation to update or revise any forward-looking-statements
contained in this press release whether as a result of new
information or future events, except as may be required by
law. Nothing contained herein constitutes or will be deemed
to constitute a forecast, projection or estimate of the future
financial performance of Assertio, Zyla, the new holding company or
the combined company, whether following the implementation of the
proposed transaction or otherwise.
No Offer or Solicitation
This communication relates to a proposed business combination
involving Assertio and Zyla. The information in this communication
is for informational purposes only and is neither an offer to
purchase, nor a solicitation of an offer to sell, subscribe for or
buy any securities or the solicitation of any vote in any
jurisdiction pursuant to the proposed transactions or otherwise,
nor shall there be any sale, issuance or transfer of securities in
any jurisdiction in contravention of applicable law. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act.
Additional Information and Where to Find
It
This communication may be deemed to be solicitation material in
respect of the proposed issuance of shares for Assertio and the
proposed Merger for Zyla. The proposed issuance of shares will be
submitted to Assertio’s stockholders and the proposed Merger will
be submitted to Zyla’s stockholders for their consideration. In
connection with the proposed Merger and the solicitation of
proxies, Assertio and Zyla have filed, and mailed to their
respective stockholders, the Joint Proxy Statement/Prospectus dated
April 20, 2020. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION
WITH RESPECT TO THE PROPOSED MERGER, INVESTORS AND STOCKHOLDERS OF
ASSERTIO AND INVESTORS AND STOCKHOLDERS OF ZYLA ARE URGED TO READ
THE DEFINITIVE REGISTRATION STATEMENT, INCLUDING THE JOINT PROXY
STATEMENT, REGARDING THE PROPOSED MERGER (INCLUDING ANY AMENDMENTS
OR SUPPLEMENTS THERETO) AND OTHER RELEVANT MATERIALS WHEN THEY
BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER.
The Joint Proxy Statement, any amendments or supplements thereto
and other relevant materials, and any other documents filed by
Assertio or Zyla with the SEC, may be obtained once such documents
are filed with the SEC free of charge at the SEC’s website at
www.sec.gov or free of charge from Assertio at www.assertiotx.com
or by directing a request to Assertio’s Investor Relations
Department at investor@assertiotx.com or free of charge from Zyla
at www.zyla.com or by directing a Zyla’s Investor Relations
Department at ir@zyla.com.
Participants in the SolicitationAssertio, Zyla
and certain of their respective executive officers, directors,
other members of management and employees may, under the rules of
the SEC, be deemed to be “participants” in the solicitation of
proxies in connection with the proposed issuance of shares and the
proposed Merger. Information regarding Assertio’s directors and
executive officers is available in its Joint Proxy
Statement/Prospectus dated April 20, 2020 and its Annual
Report on Form 10-K for the year ended December 31, 2019, that was
filed with the SEC on March 10, 2020. Information regarding Zyla’s
directors and executive officers is available in its Proxy
Statement on Schedule 14A for its 2019 Annual Meeting of
Stockholders, that was filed with the SEC on November 6, 2019 and
in its Annual Report on Form 10-K for the year ended December 31,
2019, that was filed with the SEC on March 26, 2020. These
documents may be obtained free of charge from the sources indicated
above. Other information regarding the participants in the proxy
solicitation and a description of their direct and indirect
interests, by security holdings or otherwise, is contained in the
Joint Proxy Statement/Prospectus and other relevant materials
relating to the proposed Merger to be filed with the SEC when they
become available.
Investor and Media Contact:Dan Peisert Senior
Vice President and Chief Financial
Officerdpeisert@assertiotx.com
1 Combined company pro forma results includes 2019 Cambia and
Zipsor net product sales and 2019 Zyla net product sales, as if the
transaction had occurred on January 1, 2019
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2023 to Apr 2024